FTC charges weight-loss product marketers
This article was originally published in The Tan Sheet
The Federal Trade Commission underscores that dietary supplement weight-loss claims are a top enforcement priority by charging three companies and two individuals with making false claims for diet products Relacore and Akavar 20/50. The commission seeks restitution from Basic Research, Carter-Reed, Dynakor Pharmacal and company executives Dennis Gay and Mitchell Friedlander. The suit, filed in U.S. District Court for the District of Utah, also alleges Basic Research, Gay and Friedlander violated a previous order from 2006 not to make bogus claims. The violation occurred when they advertised Relacore and Akavar as allowing users to "eat all you want and still lose weight." The case drives home the message David Vladeck, director of the Bureau of Consumer Protection, delivered in July when he said supplement weight-loss claims are a "high priority" for FTC because "false claims engender false hopes" (1"The Tan Sheet" Aug. 3, 2009)
You may also be interested in...
The Federal Trade Commission will issue updated guides later in 2009 to assist advertisers in using endorsements. Agency staff is currently analyzing comments about proposed changes to its 1980 guides, said David Vladeck, director of FTC's Bureau of Consumer Protection (1"The Tan Sheet" Dec. 1, 2008). The current "guides are not working as intended to prevent consumer deception," particularly with "typicality claims," he told the Senate Consumer Protection, Product Safety, and Insurance Subcommittee July 22. Vladeck said testimonials and endorsements still are misused, particularly with weight-loss products
When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.
Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.